Compare SII & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | IRON |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2011 | 2020 |
| Metric | SII | IRON |
|---|---|---|
| Price | $147.67 | $60.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $132.00 | $101.67 |
| AVG Volume (30 Days) | 212.7K | ★ 979.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $11.39 | $101.57 |
| P/E Ratio | $63.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.33 | $30.82 |
| 52 Week High | $169.63 | $99.50 |
| Indicator | SII | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 38.15 |
| Support Level | $79.37 | $57.81 |
| Resistance Level | $167.47 | $64.00 |
| Average True Range (ATR) | 7.95 | 3.22 |
| MACD | -1.76 | 0.08 |
| Stochastic Oscillator | 6.12 | 6.40 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.